SBIR/STTR Research Award

A Novel Inhibitor of the Classical Pathway of Complement

Award identifier a854e726d5b762a7e33964c559d6fa5935de7090e59986dec9ac892ab27994a5Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$254,235

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AnthroBio, Inc.
Proposal award date
2018-01-01
Contract end date
2019-06-30
UEI
EJC6LGMKQBF1
Solicitation number
PA16-302
Topic code
NHLBI

Research abstract

A novel inhibitor of the classical pathway of the complement system Abstract The classical pathway of the complement system is implicated in the pathogenesis of a number of human autoimmune diseasesincluding systemic lupus erythematosusrheumatoid arthritisalloantibody mediated transplant rejection and autoimmune hemolytic anemiaDespite a large body of literature documenting the role of the complement system in these disordersa specific inhibitor of the classical pathway has yet to be developedCold agglutinin diseaseCADis a type of autoimmune hemolytic anemiaAIHAIt is an orphan disease that accounts forof AIHA casesThe pathophysiology of CAD is driven by the classical pathway of the complement systemThe current treatment options for CAD are broadly immunosuppressive and are associated with a number of off target effectsWe have identified a human autoantibody that inhibits the classical pathway at the step of CactivationActivated Cis the first of two subunits that compose the classical pathway Cconvertasewhich is the central enzyme of the classical pathway of complementIn a number of autoimmune diseasesdysregulation of the classical pathway can lead to uncontrolled inflammation through the production of potent anaphylotoxins and other inflammatory mediatorsWe propose that an anti CMAb will be effective at inhibiting activation of the classical pathway in certain autoimmune diseasesIn particularwe propose that this therapeutic MAb could be used to treat cold agglutinin disease and potentially other complement mediated disordersIn this Phase I SBIRwe will characterize the Cinhibitory MAb and test it in proof of principle in vitro assays to demonstrate feasibility of this therapeutic strategy Project Narrative AnthroBio has identified a human antibody that inhibits complement activation via the classical pathwayWe hypothesize that this antibody can be developed into an effective treatment for certain autoimmune inflammatory diseases mediated by the classical pathway of complement

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.